Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.
Thanks!

Click here for a guide on disabling your adblocker.

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

CAN (QC): Thymox closes $4.6M Series B financing round

Thymox, the botanically-derived disinfectant, has announced the closing of a $4.6 million Series B financing round. The round was led by current investors, Cycle Capital Management and Desjardins Innovatech, and attracted new investors including Germain Benoit from Gercanoit. The funds will primarily be used to accelerate international commercial expansion of Thymox as a disinfectant for animal health and crop protection, and into institutional and retail markets.

“We are entering a very exciting phase of our company's growth,” said Frank Palantoni, CEO of Laboratoire M2, the makers of Thymox. “We’re extremely pleased to welcome our new investors to this round, and also to see our current investors, Desjardins Innovatech and Cycle Capital Management, participate. We now have the resources to globally commercialize our greentech disinfecting technology platform."

"Bringing a new biological solution with such broad applications into new markets is a significant challenge. We’re proud to partner with a great entrepreneurial team to meet the challenge and pursue commercial growth,” added Andrée-Lise Méthot, Founder and Managing Partner at Cycle Capital Management.

Citing the company's expanding commercial frontiers, Jacques Perreault, Vice President of Desjardins Innovatech, commented, "We are enthusiastic about partnering with the management team and the shareholders of Laboratoire M2 to support their next phase of growth and development. They have a strong business plan, their product, Thymox, is innovative, and they are evolving in a fast growing market close to Desjardin’s values." Desjardins Group is one of Canada's leading cooperative financial groups with more than $200 billion in assets.

2017 represents a major milestone year for Thymox, as the company successfully pivots from technology development to full scale commercial expansion on three continents. "We remain on track in developing Thymox sales momentum in our Animal Health business, and we are launching new products for our surface disinfecting markets," Palantoni added, "and of course, our robust pipeline of innovation includes products to meet the ever increasing demand for botanically derived crop protection products. With our accelerating commercial momentum, we expect to continue to attract partnership interest from major strategic players in the Animal Health sector."

Thymox is a biodegradable, non-toxic, concentrated disinfectant which is instantaneously dilutable and stable in water, an important advantage for all commercial applications. The effectiveness of Thymox is based on the action of thymol, a botanically derived, active ingredient found in the plant thyme. Thymox has strong anti-microbial properties and kills pathogenic microorganisms on surfaces and in agricultural settings without harming living tissue or the environment.

For more information:
Thymox
4005-A, rue de la Garlock
Sherbrooke, Quebec, Canada, J1L 1W9
T: 819-563-0698
F: 819-563-9298
www.thymox.com
Publication date: